A Randomized Controlled Study of Dose-tapering Regimen of Semaglutide for Weight-Loss Maintenance in Adults With Overweight or Obesity

The goal of this clinical trial is to determine whether a semaglutide dose‐taperingregimen is non‐inferior to a treatment‐dose maintenance regimen for weight‐lossmaintenance in adults with overweight or obesity who have achieved stable weight loss.This trial will also evaluate the safety of the dose‐tapering regimen.The primary research questions are:Is the semaglutide dose‐tapering regimen non‐inferior to the treatment‐dose maintenanceregimen for weight‐loss maintenance at 24 weeks? Can the dose‐tapering regimen alleviateadverse events and offer a more personalized, sustainable pathway for medicationdiscontinuation? Researchers will compare the semaglutide dose‐tapering regimen against atreatment‐dose maintenance regimen to assess whether the tapering strategy preservesweight loss and improves cardiometabolic markers.Participants will:Be randomly assigned to receive either the semaglutide dose‐tapering regimen or thetreatment‐dose maintenance regimen for 24 weeks.Complete a 24‐week follow‐up period after medication discontinuation (48 weeks totalstudy duration).Attend scheduled clinic visits for physical examinations and laboratory testing to assessweight, BMI, waist circumference, cardiometabolic markers (including blood glucose, bloodpressure, and lipids), and to monitor adverse events.